ArticleScientific reports2026
Self-efficacy in the managing late sequelae in long-term breast cancer survivors in Spain.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study assessed self-efficacy in managing long-term effects among breast cancer survivors living beyond five years post-diagnosis, as well as associated sociodemographic, clinical, and lifestyle factors. A cross-sectional design was conducted with 188 women recruited through intentional sampling. Recruitment was carried out through dissemination on social media, print and digital media, radio and television, as well as collaboration with regional patient associations. Sociodemographic, clinical, and lifestyle data were collected, and self-efficacy was measured using the self-efficacy for managing chronic disease scale (SEMCD-S). Analyses included descriptive statistics, bivariate tests, and multiple regression to identify predictors of self-efficacy. Participants had a mean age of 57.5 years and an average survival time of 10.2 years. The mean SEMCD-S score was 6.4 (range 0-10), indicating a moderate level of self-efficacy. Significant associations were found between self-efficacy and tobacco consumption (p < 0.05), as well as with the presence of comorbidities (p = 0.013). In the regression model, only comorbidity remained a significant negative predictor, accounting for 2.53% of the variance. In summary, long-term breast cancer survivors reported moderate self-efficacy in managing chronic disease effects. Comorbidities emerged as a key factor negatively influencing self-efficacy. These findings suggest the need for targeted interventions to enhance self-efficacy and improve quality of life in this growing survivor population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.